Efficacy and safety of BFE5264 Probiotics on serum cholesterol; A 12week, Randomized, Double-blind, Placebo-Controlled Clinical Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0002634

Enrollment

Registered

2018-01-05

Start date

2016-09-08

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Subjects will be randomized to receive Lactobacillus rhamnosus BFE5264 or placebo. Subjects will orally self-adminster Lactobacillus rhamnosus BFE5264 or placebo bid, 1 sachet per

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Male and female subjects between 20-75years of age inclusive 2) Total cholesterol of 200~239 mg/dl or LDL cholesterol of 130~189mg/dl 3) Subjects who agree the particpation in the trial and submit informed and consent before the beginning of the trial.

Exclusion criteria

Exclusion criteria: The patient who take the medicine that can affect the state of cholesterol within recent 3 months.

Design outcomes

Primary

Measure	Time frame
Total cholesterol;LDL-cholesterol ;HDL-cholesterol	—

Secondary

Measure	Time frame
Adverse event	—

Countries

Korea, Republic of

Contacts

Public ContactYong Gyun No

Hallym University Medical Center-Kangnam

rohyk@hallym.or.kr+82-2-829-5270

Outcome results